Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: The FLEX trial

Journal of Bone and Mineral Research

Volumn 25, Issue 5, 2010, Pages 976-982

  Schwartz, Ann V ^a   Bauer, Douglas C ^a   Cummings, Steven R ^b   Cauley, Jane A ^c   Ensrud, Kristine E ^d,e   Palermo, Lisa ^a   Wallace, Robert B ^f   Hochberg, Marc C ^g   Feldstein, Adrianne C ^h   Lombardi, Antonio ⁱ   Black, Dennis M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^c UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^d VA MEDICAL CENTER   (United States)

^e UNIVERSITY OF MINNESOTA   (United States)

^f UNIVERSITY OF IOWA   (United States)

^g UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

^h CENTER FOR HEALTH RESEARCH   (United States)

ⁱ MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Alendronate; Bisphosphonates; Clinical trial; Discontinuation; Fracture

Indexed keywords

ALENDRONIC ACID; CALCIUM; COLECALCIFEROL; PLACEBO;

ADULT; AGED; ARTICLE; BONE DENSITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMUR NECK; FRACTURE; HIP; HUMAN; LONG TERM CARE; LUMBAR SPINE; MAJOR CLINICAL STUDY; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SPINE RADIOGRAPHY; TREATMENT DURATION; VERTEBRA FRACTURE;

AGED; AGED, 80 AND OVER; ALENDRONATE; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DOUBLE-BLIND METHOD; FEMALE; FEMUR NECK; FRACTURES, BONE; HUMANS; MIDDLE AGED; SPINAL FRACTURES; TREATMENT OUTCOME;

EID: 77952331323     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1002/jbmr.11     Document Type: Article

References (16)

1. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures: Fracture Intervention Trial Research Group. Lancet. 1996;348:1535-1541.
2. Liberman UA, Weiss SR, Broll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis: the Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med. 1995;333:1437-1443.
3. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA. 1998;280:2077-2082.
4. Black DM, Schwartz AV, Ensrud KE, et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-Term Extension (FLEX): a randomized trial. JAMA. 2006;296:2927-2938.
5. Delmas PD. Use of alendronate after 5 years of treatment. JAMA. 2007;297:1979-1980; author reply: 1980-1981.
6. Black DM, Reiss TF, Nevitt MC, Cauley J, Karpf D, Cummings SR. Design of the Fracture Intervention Trial. Osteoporos Int. 1993;3:S29-S39.
7. Ensrud KE, Barrett-Connor EL, Schwartz A, et al. Randomized Trial of Effect of Alendronate Continuation Versus Discontinuation in Women With Low BMD: Results From the Fracture Intervention Trial Long-Term Extension. J Bone Miner Res. 2004;19:1259-1269.
8. Looker AC, Wahner HW, Dunn WL, et al. Updated data on proximal femur bone mineral levels of US adults. Osteoporos Int. 1998;8:468-489.
9. Genant HK, Wu CY, van Kuijk C, Nevitt MC. Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res. 1993;8:1137-1148.
10. Black DM, Cummings SR, Stone K, Hudes E, Palermo L, Steiger P. A new approach to defining normal vertebral dimensions. J Bone Miner Res. 1991;6:883-892.
11. Eastell R, Cedel SC, Wahner HW, Riggs BL, Melton LJ. Classification of vertebral fractures. J Bone Miner Res. 1991;6:207-215.
12. Black DM, Palermo L, Nevitt MC, et al. Comparison of methods for defining prevalent vertebral deformities: the Study of Osteoporotic Fractures. J Bone Miner Res. 1995;10:890-902.
13. Ensrud KE, Black DM, Palermo L, et al. Treatment with alendronate prevents fractures in women at highest risk: results from the Fracture Intervention Trial. Arch Intern Med. 1997;157:2617-2624.
14. Cummings SR. A 55-year-old woman with osteopenia. Jama. 2006; 296:2601-2610.
15. McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med. 2001;344:333-340.
16. Recker R, Masarachia P, Santora A, et al. Trabecular bone microarchitecture after alendronate treatment of osteoporotic women. Curr Med Res Opin. 2005;21:185-194.